105858.jpg
Tomorrow I've pharmacology practical exam and the topic is P drug. Answer the above question in following category: 1. P group 2. P drug And each category should have following सब categories: 1. Drug 2. Safety 3. Efficiency 3. Suitability 4. Cost Also mention the dose and frequency of the P drug MBBS PHARMACOLOGY 2ND YEAR
Reading File
The image shows 18 conditions for a P drug practical exam. Given the large number of topics, I need to know which specific condition you want answered. But given the exam context, let me provide answers for ALL 18 conditions efficiently. First, let me search the medical library for key topics simultaneously.
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Here is the complete P Drug practical answer guide for all 18 topics from your image. The format used is standard MBBS 2nd year pharmacology practical P drug format.
P DRUG PRACTICAL - COMPLETE ANSWER GUIDE
MBBS 2nd Year Pharmacology
What is P Drug? A "Personal Drug" (P Drug) is the drug you choose as your drug of first choice for a given condition, based on Efficacy, Safety, Suitability, and Cost (ESSC criteria).
1. VERTIGO
| Category | Details |
|---|---|
| P Group | Antihistaminics (H1 blockers with vestibular suppressant action) |
| P Drug | Cinnarizine |
| Drug | Cinnarizine - acts on H1 receptors and also has Ca2+ channel blocking activity on vestibular system |
| Efficacy | Effective in reducing vertigo, nausea, and vomiting; acts on both central and peripheral vestibular system |
| Safety | Well tolerated; may cause drowsiness, dry mouth; avoid in Parkinson's disease |
| Suitability | Suitable for most adults including elderly; oral administration; avoid in pregnancy |
| Cost | Inexpensive, widely available |
| Dose & Frequency | 25 mg TDS (three times a day) orally |
2. ACUTE ATTACK OF MILD MIGRAINE
| Category | Details |
|---|---|
| P Group | NSAIDs / Mild analgesics |
| P Drug | Aspirin (or Ibuprofen) |
| Drug | Aspirin - inhibits COX-1 and COX-2, reduces prostaglandin synthesis; also inhibits platelet aggregation |
| Efficacy | Effective for mild-to-moderate migraine attacks; reduces headache, nausea |
| Safety | Avoid in peptic ulcer disease, bleeding disorders, children <16 yrs (Reye's syndrome); avoid in asthmatics |
| Suitability | Suitable for adults without contraindications; can be combined with metoclopramide for better absorption |
| Cost | Very cheap, widely available |
| Dose & Frequency | 600-900 mg as a single dose at onset of attack; can repeat after 4-6 hrs; max 4g/day |
3. ACUTE ATTACK OF SEVERE MIGRAINE
| Category | Details |
|---|---|
| P Group | 5-HT1B/1D receptor agonists (Triptans) |
| P Drug | Sumatriptan |
| Drug | Sumatriptan - selective 5-HT1B/1D agonist; causes cranial vasoconstriction, inhibits neuropeptide release, reduces neurogenic inflammation |
| Efficacy | Gold standard for acute severe migraine; relieves headache, nausea, photophobia within 1-2 hrs; most effective antimigraine drug |
| Safety | Contraindicated in IHD, uncontrolled hypertension, hemiplegic/basilar migraine, pregnancy; may cause chest tightness, flushing, paresthesia ("triptan sensations") |
| Suitability | Suitable for adults with severe migraine not responding to NSAIDs; not for prophylaxis |
| Cost | Expensive compared to NSAIDs but cost-effective for severe attacks |
| Dose & Frequency | 50-100 mg oral at onset; may repeat after 2 hrs if needed; max 300 mg/day. SC: 6 mg subcutaneously; Nasal spray: 10-20 mg |
4. ACUTE CONGESTIVE GLAUCOMA
| Category | Details |
|---|---|
| P Group | Osmotic diuretics + Carbonic anhydrase inhibitors |
| P Drug | Acetazolamide (systemic) + Pilocarpine (topical) |
| Drug | Acetazolamide - carbonic anhydrase inhibitor; reduces aqueous humor production. Pilocarpine - direct muscarinic agonist; opens trabecular meshwork by pupillary constriction |
| Efficacy | Rapidly lowers IOP in acute angle closure; Pilocarpine opens drainage angle |
| Safety | Acetazolamide: avoid in sulfa allergy, hepatic/renal failure; may cause metabolic acidosis, hypokalemia. Pilocarpine: may cause spasm of accommodation, brow ache |
| Suitability | Emergency use; once pupil responds to pilocarpine, definitive surgery (iridotomy) is the cure |
| Cost | Moderate; both available widely |
| Dose & Frequency | Acetazolamide: 500 mg IV immediately, then 250 mg orally QID. Pilocarpine: 2% eye drops - 1 drop every 15 min for 1 hour, then every 6 hrs |
5. OPEN ANGLE GLAUCOMA
| Category | Details |
|---|---|
| P Group | Prostaglandin analogs (topical) |
| P Drug | Latanoprost |
| Drug | Latanoprost - FP prostaglandin receptor agonist; increases uveoscleral outflow of aqueous humor |
| Efficacy | Most effective single agent for reducing IOP (reduces by 25-35%); once daily dosing enhances compliance |
| Safety | Local side effects: iris pigmentation, eyelash growth (hypertrichosis), conjunctival hyperemia; avoid in uveitic glaucoma |
| Suitability | First-line for open angle glaucoma; once-nightly dosing; suitable for most patients |
| Cost | Moderately expensive but cost-effective due to once-daily dosing |
| Dose & Frequency | 0.005% eye drops, 1 drop once daily at bedtime |
Alternative P Drug: Timolol 0.5% - beta blocker, 1 drop BD, cheaper but contraindicated in asthma/COPD/heart block
6. ANAPHYLACTIC SHOCK
| Category | Details |
|---|---|
| P Group | Sympathomimetic amines / Catecholamines |
| P Drug | Adrenaline (Epinephrine) |
| Drug | Epinephrine - acts on α1 (vasoconstriction, raises BP), β1 (increases HR and contractility), β2 (bronchodilation); physiologic antagonist of anaphylaxis mediators |
| Efficacy | ONLY life-saving drug in anaphylaxis; reverses all features - bronchospasm, hypotension, urticaria, angioedema; acts within minutes |
| Safety | May cause palpitations, arrhythmias, hypertensive crisis; use cautiously in elderly/cardiac patients; but benefits always outweigh risks in anaphylaxis |
| Suitability | IM route preferred (anterolateral thigh); suitable for all ages including children; no absolute contraindication in anaphylaxis |
| Cost | Very cheap, universally available |
| Dose & Frequency | 0.5 mg (0.5 mL of 1:1000) IM in anterolateral thigh; repeat every 5-15 min as needed. Children: 0.01 mg/kg |
7. UNCOMPLICATED FALCIPARUM MALARIA
| Category | Details |
|---|---|
| P Group | Artemisinin-based Combination Therapy (ACT) |
| P Drug | Artemether + Lumefantrine (Coartem) |
| Drug | Artemether - rapidly acting blood schizonticide, acts on all stages; Lumefantrine - partner drug prevents recrudescence; combination prevents resistance |
| Efficacy | WHO first-line for uncomplicated P. falciparum; cure rate >95%; works even against chloroquine-resistant strains |
| Safety | Generally well tolerated; may cause nausea, dizziness, QT prolongation (mild); avoid in 1st trimester of pregnancy |
| Suitability | Oral formulation; suitable for adults and children; take with fatty food to enhance absorption |
| Cost | Moderately expensive; available free/subsidized through NVBDCP in India |
| Dose & Frequency | Artemether 20mg + Lumefantrine 120mg - 4 tablets at 0, 8, 24, 36, 48, 60 hours (6 doses total for adults >35 kg) |
Note: In India, ACT (Artesunate + SP + Primaquine) is the national program drug for Pf malaria
8. SHIGELLOSIS (Acute Bacterial Dysentery)
| Category | Details |
|---|---|
| P Group | Fluoroquinolones |
| P Drug | Ciprofloxacin |
| Drug | Ciprofloxacin - inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV; bactericidal against gram-negative organisms including Shigella |
| Efficacy | Drug of choice for Shigellosis; shortens illness duration, reduces transmission; highly effective against Shigella spp. |
| Safety | Avoid in children <12 yrs (cartilage toxicity), pregnancy, tendon disorders; may cause GI upset, photosensitivity, QT prolongation |
| Suitability | Oral route; short course (3-5 days) effective; ORS must accompany antibiotics |
| Cost | Inexpensive, widely available as generic |
| Dose & Frequency | 500 mg BD (twice daily) for 3-5 days |
9. TYPHOID FEVER
| Category | Details |
|---|---|
| P Group | Fluoroquinolones |
| P Drug | Ciprofloxacin |
| Drug | Ciprofloxacin - bactericidal against Salmonella typhi; achieves high intracellular concentration within macrophages where the bacteria reside |
| Efficacy | Highly effective; defervescence in 3-5 days; low relapse rate; short course treatment possible |
| Safety | Same as above; avoid in children, pregnancy |
| Suitability | Oral administration; 7-10 day course standard |
| Cost | Very cheap as generic |
| Dose & Frequency | 500 mg BD (twice daily) for 7-10 days |
Alternative: Azithromycin 1g on day 1, then 500mg OD for 6 days (preferred in pregnancy and children)
10. PULMONARY EDEMA DUE TO LEFT-SIDED CHF
| Category | Details |
|---|---|
| P Group | Loop diuretics |
| P Drug | Furosemide (Frusemide) |
| Drug | Furosemide - inhibits Na+/K+/2Cl- cotransporter in thick ascending limb of Loop of Henle; causes massive diuresis; also has early venodilatory effect (within 5 min of IV) that reduces preload before diuresis begins |
| Efficacy | Most powerful diuretic; most effective drug for acute pulmonary edema; dual mechanism (early venodilation + later diuresis); reduces dyspnea rapidly |
| Safety | May cause hypokalemia, hyponatremia, ototoxicity (with high doses), hyperuricemia, hyperglycemia; not safe in anuria |
| Suitability | IV route in acute setting; suitable for all adults; monitor electrolytes and urine output |
| Cost | Very cheap, universally available |
| Dose & Frequency | Acute pulmonary edema: 40 mg IV slow injection; may repeat with 80 mg if inadequate response. Maintenance: 20-80 mg OD orally |
11. HYPERTENSION IN PREGNANT WOMAN (PREECLAMPSIA)
| Category | Details |
|---|---|
| P Group | Centrally acting alpha-2 agonists / Vasodilators |
| P Drug | Methyldopa |
| Drug | Methyldopa - converted to alpha-methylnorepinephrine in CNS; acts on central α2 receptors to reduce sympathetic outflow; reduces peripheral vascular resistance |
| Efficacy | Effective antihypertensive; proven long-term safety record for fetus and mother in pregnancy; most studied drug in obstetric hypertension |
| Safety | SAFE in pregnancy (Category B); fetal safety well documented. May cause sedation, dry mouth, hemolytic anemia, positive Coombs test, hepatotoxicity |
| Suitability | Drug of CHOICE for chronic hypertension in pregnancy; for acute severe hypertension in preeclampsia, IV labetalol or hydralazine is used |
| Cost | Cheap, widely available |
| Dose & Frequency | 250 mg BD-TDS initially; usual maintenance 500 mg - 2g/day in divided doses |
For acute severe HTN in preeclampsia (BP >160/110): IV Labetalol or IV Hydralazine 5 mg IV bolus
12. STABLE ANGINA
| Category | Details |
|---|---|
| P Group | Beta-adrenergic blockers |
| P Drug | Atenolol |
| Drug | Atenolol - selective β1 blocker; reduces heart rate, myocardial contractility, and oxygen demand; increases diastolic filling time (improves coronary perfusion) |
| Efficacy | Reduces frequency and severity of angina attacks; reduces mortality post-MI; prevents exercise-induced angina; no tolerance develops |
| Safety | Contraindicated in asthma/COPD, bradycardia, heart block, decompensated heart failure; may cause fatigue, cold extremities, mask hypoglycemia |
| Suitability | First-line for stable angina; once or twice daily dosing; especially preferred in patients with hypertension, post-MI, tachycardia |
| Cost | Very cheap, widely available |
| Dose & Frequency | 25-100 mg OD (once daily) |
For acute attack of angina: Sublingual glyceryl trinitrate (GTN) 0.5 mg stat
13. PARKINSONISM
| Category | Details |
|---|---|
| P Group | Dopamine precursor + Decarboxylase inhibitor |
| P Drug | Levodopa + Carbidopa (Co-careldopa) |
| Drug | Levodopa - converted to dopamine in CNS; replenishes depleted striatal dopamine. Carbidopa - peripheral DOPA decarboxylase inhibitor; prevents peripheral conversion of levodopa, reducing side effects and increasing CNS availability |
| Efficacy | Most effective drug for Parkinsonism; best symptomatic relief of tremor, rigidity, bradykinesia; gold standard |
| Safety | May cause nausea, vomiting, dyskinesias, on-off phenomenon, psychosis; avoid in narrow angle glaucoma, psychosis. Long-term use causes wearing-off and peak-dose dyskinesias |
| Suitability | For patients with significant functional impairment; start low, go slow; not suitable as first-line in young patients (<60 yrs) - prefer dopamine agonists (pramipexole) to delay levodopa |
| Cost | Moderately priced; available as generic |
| Dose & Frequency | Initially Carbidopa 25mg + Levodopa 100mg (Syndopa-Plus) TDS; titrate up slowly; usual maintenance up to 200/800 mg per day in divided doses |
14. OSTEOPOROSIS
| Category | Details |
|---|---|
| P Group | Bisphosphonates |
| P Drug | Alendronate (Alendronic acid) |
| Drug | Alendronate - inhibits osteoclast-mediated bone resorption by incorporating into bone matrix and disrupting osteoclast farnesyl pyrophosphate synthase; antiresorptive |
| Efficacy | Reduces vertebral and hip fracture risk by ~50%; increases bone mineral density (BMD); best evidence base among all anti-osteoporosis drugs |
| Safety | GI irritation, esophageal ulceration (must take with full glass of water, remain upright for 30 min); osteonecrosis of jaw (rare, with long-term use); atrial fibrillation; atypical femoral fractures |
| Suitability | First-line for postmenopausal osteoporosis and steroid-induced osteoporosis; weekly dosing improves compliance; must be given with calcium + Vit D supplementation |
| Cost | Cheap (generic available); weekly formulation reduces cost |
| Dose & Frequency | 70 mg once weekly orally (morning, fasting, with plain water only, sit upright 30 min) |
15. OSTEOARTHRITIS OF BOTH KNEES
| Category | Details |
|---|---|
| P Group | Analgesics (non-opioid) |
| P Drug | Paracetamol (Acetaminophen) |
| Drug | Paracetamol - inhibits COX enzymes in CNS (central action); also activates descending serotonergic pathways; analgesic and antipyretic, NO anti-inflammatory action |
| Efficacy | Effective for mild-moderate OA pain; first-line analgesic per ACR/EULAR guidelines for OA |
| Safety | SAFEST analgesic; no GI ulceration, no platelet inhibition, no renal prostaglandin inhibition; hepatotoxic only in overdose (>4g/day) or with alcohol |
| Suitability | Suitable for elderly, those with peptic ulcer, renal impairment, cardiac disease; preferred over NSAIDs in OA |
| Cost | Extremely cheap, universally available |
| Dose & Frequency | 500 mg - 1g TDS to QID (up to 4g/day maximum); regular scheduled dosing better than PRN |
16. ACUTE GOUTY ARTHRITIS
| Category | Details |
|---|---|
| P Group | NSAIDs (for acute attack) |
| P Drug | Indomethacin |
| Drug | Indomethacin - potent non-selective COX inhibitor; reduces prostaglandin synthesis; also inhibits urate crystal phagocytosis and neutrophil migration into joint |
| Efficacy | Most effective NSAID for acute gout; rapid relief of inflammation and pain within 24-48 hrs; drug of choice for acute gouty attack |
| Safety | GI irritation (take with food), peptic ulceration, fluid retention, renal impairment; avoid in renal failure, peptic ulcer, elderly |
| Suitability | Short course (5-7 days) during acute attack only; not for chronic use; combine with PPI for GI protection |
| Cost | Cheap, widely available |
| Dose & Frequency | 50 mg TDS for 2-3 days, then taper; or 75 mg BD for 5-7 days |
Alternative for gout: Colchicine 0.5-1 mg BD for 5 days (preferred in elderly/cardiac patients who can't tolerate NSAIDs)
17. RHEUMATOID ARTHRITIS
| Category | Details |
|---|---|
| P Group | Disease Modifying Anti-Rheumatic Drugs (DMARDs) |
| P Drug | Methotrexate (MTX) |
| Drug | Methotrexate - folate antagonist; inhibits DHFR (dihydrofolate reductase); reduces lymphocyte proliferation and inflammatory cytokine production; immunosuppressive and anti-inflammatory |
| Efficacy | Anchor drug / gold standard DMARD for RA; slows disease progression, reduces erosions, improves function; most widely used DMARD worldwide |
| Safety | Hepatotoxicity, bone marrow suppression, pulmonary toxicity (MTX pneumonitis), teratogenicity, mucositis; must give folic acid supplementation 5mg/day to reduce side effects; regular LFT and CBC monitoring |
| Suitability | Weekly dosing improves compliance; must avoid alcohol; contraindicated in pregnancy (Category X), significant renal/hepatic disease; use effective contraception |
| Cost | Very cheap, widely available |
| Dose & Frequency | 7.5-25 mg once weekly (oral or SC/IM); start with 7.5-10 mg/week, increase by 2.5 mg every 4-6 weeks |
18. TYPE 2 DIABETES MELLITUS (Maturity Onset Diabetes)
| Category | Details |
|---|---|
| P Group | Biguanides |
| P Drug | Metformin |
| Drug | Metformin - activates AMP-activated protein kinase (AMPK); primarily reduces hepatic gluconeogenesis; also improves peripheral insulin sensitivity; does NOT cause hypoglycemia |
| Efficacy | First-line drug for T2DM per all major guidelines (ADA, IDF); reduces HbA1c by 1-2%; also has cardiovascular protective effects (UKPDS); no weight gain |
| Safety | GI side effects (nausea, diarrhea) - mitigated by taking with food; most serious risk: lactic acidosis (rare); contraindicated in renal impairment (eGFR <30), liver disease, heart failure, alcoholism; hold before contrast |
| Suitability | Drug of choice for T2DM, especially overweight/obese patients; no hypoglycemia; cardioprotective; cheap; suitable for most patients |
| Cost | Very cheap, generic widely available |
| Dose & Frequency | 500 mg OD or BD with meals initially; titrate up to 1000 mg BD (max 2.5g/day); Extended release: 500-2000 mg OD at dinner |
QUICK REFERENCE SUMMARY TABLE
| # | Condition | P Group | P Drug | Dose |
|---|---|---|---|---|
| 1 | Vertigo | Antihistaminics | Cinnarizine | 25 mg TDS |
| 2 | Mild Migraine | NSAIDs | Aspirin | 600-900 mg stat |
| 3 | Severe Migraine | Triptans | Sumatriptan | 50-100 mg stat |
| 4 | Acute Glaucoma | CA inhibitor + Miotic | Acetazolamide + Pilocarpine | 500 mg IV + 2% drops |
| 5 | Open Angle Glaucoma | Prostaglandin analog | Latanoprost | 0.005% 1 drop OD HS |
| 6 | Anaphylaxis | Sympathomimetic | Adrenaline | 0.5 mg IM (1:1000) |
| 7 | Falciparum Malaria | ACT | Artemether-Lumefantrine | 4 tabs x 6 doses |
| 8 | Shigellosis | Fluoroquinolone | Ciprofloxacin | 500 mg BD x 3-5 days |
| 9 | Typhoid | Fluoroquinolone | Ciprofloxacin | 500 mg BD x 7-10 days |
| 10 | Pulmonary Edema | Loop diuretic | Furosemide | 40-80 mg IV |
| 11 | HTN in Pregnancy | Alpha-2 agonist | Methyldopa | 250 mg BD-TDS |
| 12 | Stable Angina | Beta-blocker | Atenolol | 25-100 mg OD |
| 13 | Parkinsonism | Levodopa + DCI | Levodopa + Carbidopa | 100/25 mg TDS |
| 14 | Osteoporosis | Bisphosphonate | Alendronate | 70 mg once weekly |
| 15 | Osteoarthritis | Analgesic | Paracetamol | 500 mg-1g TDS-QID |
| 16 | Acute Gout | NSAID | Indomethacin | 50 mg TDS x 5-7 days |
| 17 | Rheumatoid Arthritis | DMARD | Methotrexate | 7.5-25 mg once weekly |
| 18 | Type 2 DM | Biguanide | Metformin | 500-1000 mg BD |
Key Exam Tips:
- Always justify your P drug choice using ESSC criteria (Efficacy, Safety, Suitability, Cost)
- Mention at least one important contraindication and one side effect for Safety
- For Suitability - mention route of administration and any special population consideration
- For acute conditions (Anaphylaxis, Pulmonary Edema, Acute Glaucoma) - emphasize speed of action
Good luck in your practical tomorrow! 🎯
Do it in a tabular method. Also mention all the p groups possible then select the best group. Then mention all drugs in that group and then select the best p drug out of it. In safety also mention adverse reaction of drugs
Here is the complete P Drug practical guide in full tabular format for all 18 conditions:
P DRUG PRACTICAL - COMPLETE TABULAR FORMAT
MBBS 2nd Year Pharmacology
1. VERTIGO
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Antihistaminics (H1 blockers) ✅ SELECTED | Vestibular suppressant + antiemetic; most effective for vertigo |
| 2 | Anticholinergics (Scopolamine) | Effective but more side effects (dry mouth, blurred vision, confusion in elderly) |
| 3 | Benzodiazepines (Diazepam) | Sedation, dependence risk; reserved for severe/refractory cases |
| 4 | Dopamine antagonists (Metoclopramide) | Mainly antiemetic; less specific for vestibular suppression |
P DRUG SELECTION
| # | Drugs in P Group (Antihistaminics) | Reason to Select / Reject |
|---|---|---|
| 1 | Cinnarizine ✅ SELECTED | H1 blocker + Ca2+ channel blocker on vestibular system; dual action, best profile |
| 2 | Promethazine | Effective but more sedating; anticholinergic side effects |
| 3 | Meclizine | Good but less available in India; OD dosing but weaker vestibular action |
| 4 | Diphenhydramine | Strong sedation; short duration of action |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Antihistaminics (H1 blockers) |
| P Drug | Cinnarizine |
| Drug (Mechanism) | H1 receptor blocker + calcium channel blocker; suppresses vestibular nucleus excitability and reduces endolymph pressure |
| Efficacy | Effective for peripheral and central vertigo; reduces nausea, vomiting, and dizziness; dual mechanism gives advantage |
| Safety | Generally safe. Adverse Reactions: Drowsiness, sedation, dry mouth, weight gain, extrapyramidal symptoms (with long-term use), depression; avoid in Parkinson's disease |
| Suitability | Oral route; suitable for adults and elderly; avoid in pregnancy (1st trimester); caution in Parkinson's |
| Cost | Cheap, widely available as generic |
| Dose & Frequency | 25 mg TDS orally |
2. ACUTE ATTACK OF MILD MIGRAINE
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | NSAIDs / Simple Analgesics ✅ SELECTED | First-line for mild attacks; effective, cheap, widely available |
| 2 | Triptans (5-HT1B/D agonists) | Reserved for moderate-severe migraine; expensive; overkill for mild attacks |
| 3 | Ergot alkaloids | Significant vasoconstrictor side effects; second-line |
| 4 | Antiemetics (Metoclopramide) | Used adjunctively, not primary treatment |
| 5 | Opioids | Dependence risk; not recommended for migraine |
P DRUG SELECTION
| # | Drugs in P Group (NSAIDs/Analgesics) | Reason to Select / Reject |
|---|---|---|
| 1 | Aspirin ✅ SELECTED | Cheap, effective, also has antiplatelet benefit; well studied in migraine |
| 2 | Ibuprofen | Also effective; alternative P drug but narrower GI safety window |
| 3 | Naproxen | Longer acting but slower onset |
| 4 | Paracetamol | Weaker efficacy in migraine; lacks anti-inflammatory action |
| 5 | Diclofenac | Effective but more GI and CV risk |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | NSAIDs (Non-Selective COX inhibitors) |
| P Drug | Aspirin |
| Drug (Mechanism) | Irreversibly inhibits COX-1 and COX-2; reduces prostaglandin and thromboxane synthesis; also has antiplatelet and mild anti-inflammatory action |
| Efficacy | Effective for mild-moderate migraine; can be combined with metoclopramide (10 mg) to enhance absorption and add antiemetic effect |
| Safety | Adverse Reactions: GI irritation, peptic ulceration, GI bleeding, hypersensitivity (aspirin-sensitive asthma), Reye's syndrome (children <16 yrs), tinnitus at high doses, platelet inhibition leading to bleeding |
| Suitability | Oral route; avoid in peptic ulcer, bleeding disorders, children, aspirin-sensitive asthma, 3rd trimester pregnancy |
| Cost | Extremely cheap |
| Dose & Frequency | 600-900 mg as single dose at onset; repeat after 4-6 hrs if needed; max 4g/day |
3. ACUTE ATTACK OF SEVERE MIGRAINE
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | 5-HT1B/1D Receptor Agonists (Triptans) ✅ SELECTED | Most effective, migraine-specific; gold standard for severe attacks |
| 2 | NSAIDs | Insufficient for severe migraine |
| 3 | Ergot alkaloids (Ergotamine) | Effective but non-selective vasoconstrictor; more dangerous side effects; triptans are superior |
| 4 | Opioids | Dependence, not recommended; may worsen nausea |
| 5 | Antiemetics alone | Insufficient as monotherapy for severe headache |
P DRUG SELECTION
| # | Drugs in P Group (Triptans) | Reason to Select / Reject |
|---|---|---|
| 1 | Sumatriptan ✅ SELECTED | First triptan; most evidence; multiple routes (oral/SC/nasal); benchmark drug |
| 2 | Rizatriptan | Faster onset; oral; alternative but less data than sumatriptan |
| 3 | Eletriptan | Good CNS penetration; higher efficacy but more expensive |
| 4 | Naratriptan | Slower onset; better tolerated; for patients with side effects to sumatriptan |
| 5 | Frovatriptan | Longest half-life (26 hrs); preferred for menstrual migraine |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | 5-HT1B/1D Receptor Agonists (Triptans) |
| P Drug | Sumatriptan |
| Drug (Mechanism) | Selective 5-HT1B/1D agonist → cranial vasoconstriction, inhibits trigeminal neuropeptide (CGRP, substance P) release, blocks central pain transmission |
| Efficacy | Gold standard for acute severe migraine; relieves headache in 70-80% within 2 hrs; also relieves nausea, photophobia, phonophobia; available in oral, SC, nasal spray forms |
| Safety | Adverse Reactions: "Triptan sensations" - chest tightness/pressure, flushing, paresthesia of neck/jaw/chest; nausea, dizziness, somnolence; coronary vasospasm (rare). Contraindicated: IHD, uncontrolled HTN, hemiplegic/basilar migraine, pregnancy, within 24 hrs of ergotamine |
| Suitability | Adults with moderate-severe migraine; not for prophylaxis; SC route useful when vomiting prevents oral intake |
| Cost | Moderately expensive but cost-effective for severe disabling attacks |
| Dose & Frequency | Oral: 50-100 mg stat; repeat after 2 hrs if needed; max 300 mg/day. SC: 6 mg subcutaneously. Nasal: 10-20 mg |
4. ACUTE CONGESTIVE (ANGLE CLOSURE) GLAUCOMA
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Carbonic Anhydrase Inhibitors (systemic) ✅ SELECTED | Rapidly reduces aqueous humor production; IV route for emergency |
| 2 | Osmotic agents (Mannitol) | Also rapidly reduces IOP; used if CA inhibitor inadequate |
| 3 | Miotics (Pilocarpine - topical) | Opens drainage angle; used alongside systemic drugs |
| 4 | Beta-blockers (topical) | Reduce production but slower onset; adjunct use |
| 5 | Prostaglandin analogs | Too slow for acute emergency |
P DRUG SELECTION
| # | Drugs in CA Inhibitor Group | Reason to Select / Reject |
|---|---|---|
| 1 | Acetazolamide ✅ SELECTED | IV/oral; most used in acute glaucoma emergency; well-studied |
| 2 | Dorzolamide | Topical only; for open angle; not potent enough for acute attack |
| 3 | Brinzolamide | Topical only; adjunct therapy |
| 4 | Mannitol (adjunct) | IV osmotic; use if IOP not controlled by acetazolamide |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Carbonic Anhydrase Inhibitors + Miotic (Pilocarpine) |
| P Drug | Acetazolamide (systemic) + Pilocarpine 2% (topical) |
| Drug (Mechanism) | Acetazolamide: inhibits carbonic anhydrase in ciliary epithelium → reduces aqueous humor production → lowers IOP. Pilocarpine: M3 muscarinic agonist → pupillary constriction → pulls iris away from drainage angle → opens trabecular meshwork |
| Efficacy | Combination rapidly reduces IOP; acetazolamide acts within 30 min; pilocarpine opens blocked angle mechanically; definitive treatment is laser iridotomy |
| Safety | Acetazolamide ADRs: Metabolic acidosis, hypokalemia, paresthesia, sulfonamide hypersensitivity, renal stones, malaise. Pilocarpine ADRs: Spasm of accommodation (blurred vision), brow ache, miosis causing dim vision, retinal detachment (rare in high myopia) |
| Suitability | Emergency use only; once IOP controlled, laser peripheral iridotomy is the cure; Acetazolamide contraindicated in sulfa allergy, severe hepatic/renal disease |
| Cost | Both cheap and widely available |
| Dose & Frequency | Acetazolamide: 500 mg IV stat, then 250 mg orally QID. Pilocarpine 2% eye drops - 1 drop every 15 min × 4 doses, then every 6 hrs |
5. OPEN ANGLE GLAUCOMA
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Prostaglandin Analogs (topical) ✅ SELECTED | Most effective IOP reduction (25-35%); once daily; best compliance |
| 2 | Beta-blockers (topical) - Timolol | Effective, cheap; but systemic absorption causes bradycardia, bronchospasm |
| 3 | Alpha-2 agonists (Brimonidine) | Effective adjunct; systemic side effects (drowsiness, dry mouth) |
| 4 | Carbonic anhydrase inhibitors (topical) | Adjunct; less potent than PGAs |
| 5 | Miotics (Pilocarpine) | Effective but intolerable side effects (accommodative spasm, brow ache); 4x/day dosing |
P DRUG SELECTION
| # | Drugs in Prostaglandin Analog Group | Reason to Select / Reject |
|---|---|---|
| 1 | Latanoprost ✅ SELECTED | First PGA; most evidence; cheap generic available; gold standard |
| 2 | Bimatoprost | Slightly more effective; used in eyelash growth products; expensive |
| 3 | Travoprost | Similar efficacy to latanoprost |
| 4 | Tafluprost | Preservative-free; for patients with preservative allergy |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Prostaglandin Analogs (FP receptor agonists) |
| P Drug | Latanoprost |
| Drug (Mechanism) | FP prostanoid receptor agonist → increases uveoscleral outflow (unconventional pathway) → reduces IOP; does NOT affect aqueous humor production |
| Efficacy | Reduces IOP by 25-35%; most effective single topical agent; once-nightly dosing improves compliance; additive with beta-blockers and CA inhibitors |
| Safety | Adverse Reactions: Iris pigmentation (permanent, due to melanin increase), periorbital skin darkening, eyelash hypertrichosis (lengthening and darkening), conjunctival hyperemia; rarely - cystoid macular edema, uveitis |
| Suitability | First-line for POAG; once daily at bedtime; avoid in uveitic glaucoma; caution in aphakic/pseudophakic eyes (CME risk) |
| Cost | Moderately priced; generic available |
| Dose & Frequency | Latanoprost 0.005% - 1 drop OD at bedtime |
6. ANAPHYLACTIC SHOCK
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Sympathomimetic Amines (Catecholamines) ✅ SELECTED | Only class that is truly life-saving; physiologic antagonist; acts on all mediators simultaneously |
| 2 | Corticosteroids (Hydrocortisone) | Delayed onset (4-6 hrs); adjunct only; cannot replace epinephrine |
| 3 | Antihistaminics (Chlorpheniramine) | Block only H1 effects; do not reverse bronchospasm or hypotension; adjunct only |
| 4 | Bronchodilators (Salbutamol) | For bronchospasm component only; not for systemic anaphylaxis |
| 5 | IV fluids | Supportive; not primary treatment |
P DRUG SELECTION
| # | Drugs in Sympathomimetic Group | Reason to Select / Reject |
|---|---|---|
| 1 | Adrenaline (Epinephrine) ✅ SELECTED | Acts on α1 + β1 + β2; reverses ALL features of anaphylaxis simultaneously; NO alternative |
| 2 | Noradrenaline | Lacks β2 action; would worsen bronchospasm; NOT suitable |
| 3 | Dopamine | Primarily renal/cardiac doses; NOT appropriate for anaphylaxis |
| 4 | Phenylephrine | Only α1; no bronchodilation; NOT suitable |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Sympathomimetic Amines / Catecholamines |
| P Drug | Adrenaline (Epinephrine) |
| Drug (Mechanism) | α1: vasoconstriction → reverses hypotension, reduces angioedema. β1: positive inotrope/chronotrope → increases cardiac output. β2: bronchodilation → relieves bronchospasm. Also inhibits mast cell degranulation |
| Efficacy | The ONLY life-saving drug; reverses hypotension, bronchospasm, urticaria, and angioedema within minutes; no other drug can replace it in anaphylaxis |
| Safety | Adverse Reactions: Palpitations, tachycardia, ventricular arrhythmias, hypertensive crisis, anxiety, tremor, headache, pulmonary edema (with IV overdose). Note: In anaphylaxis, benefits ALWAYS outweigh risks - there are NO absolute contraindications |
| Suitability | IM route in anterolateral thigh (vastus lateralis) is preferred; faster absorption than SC; IV only in cardiac arrest. Suitable for ALL ages including children and pregnant women |
| Cost | Very cheap; available in all emergency settings |
| Dose & Frequency | 0.5 mg IM (0.5 mL of 1:1000 solution) in anterolateral thigh; repeat every 5-15 min as needed. Children: 0.01 mg/kg IM |
7. UNCOMPLICATED FALCIPARUM MALARIA
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Artemisinin-based Combination Therapy (ACT) ✅ SELECTED | WHO & NVBDCP first-line; effective against resistant strains; prevents resistance development |
| 2 | Chloroquine | Drug of choice for sensitive Pf malaria; BUT widespread resistance limits use for falciparum |
| 3 | Atovaquone-Proguanil | Effective; expensive; mainly for travelers/prophylaxis |
| 4 | Quinine | Second-line; reserved for severe/complicated malaria; many side effects (cinchonism) |
| 5 | Mefloquine | Effective but neuropsychiatric side effects; resistance in SE Asia |
P DRUG SELECTION
| # | Drugs in ACT Group | Reason to Select / Reject |
|---|---|---|
| 1 | Artemether + Lumefantrine ✅ SELECTED | WHO preferred; >95% cure rate; good tolerability; widely available (Coartem) |
| 2 | Artesunate + Amodiaquine | WHO alternative ACT; higher risk of agranulocytosis with amodiaquine |
| 3 | Artesunate + Mefloquine | Used in SE Asia; mefloquine neuropsychiatric effects limit use |
| 4 | Artesunate + SP (Sulfadoxine-Pyrimethamine) | NVBDCP regimen in India; resistance to SP growing |
| 5 | Dihydroartemisinin + Piperaquine | Alternative ACT; once daily; used in some countries |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Artemisinin-based Combination Therapy (ACT) |
| P Drug | Artemether + Lumefantrine (Coartem) |
| Drug (Mechanism) | Artemether: rapidly cleaved to dihydroartemisinin; generates free radicals that damage parasite proteins and membranes; acts on all asexual stages. Lumefantrine: partner drug; inhibits heme detoxification; long half-life prevents recrudescence and reduces resistance selection |
| Efficacy | >95% cure rate for uncomplicated P. falciparum including chloroquine-resistant strains; reduces gametocyte carriage |
| Safety | Adverse Reactions: Nausea, vomiting, dizziness, headache, palpitations, mild QTc prolongation; well tolerated overall. Avoid in 1st trimester of pregnancy (use quinine + clindamycin instead) |
| Suitability | Oral formulation; take with fatty food (increases lumefantrine absorption 16x); for adults and children >5 kg; not for severe malaria (use IV artesunate) |
| Cost | Moderately priced; available free through NVBDCP in India |
| Dose & Frequency | Adults (>35 kg): 4 tablets (each: Artemether 20mg + Lumefantrine 120mg) at 0, 8, 24, 36, 48, 60 hours (total 6 doses over 3 days) |
8. SHIGELLOSIS (ACUTE BACTERIAL DYSENTERY)
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Fluoroquinolones ✅ SELECTED | Bactericidal against Shigella; good tissue penetration; short course effective |
| 2 | Azithromycin | Alternative for fluoroquinolone-resistant Shigella; preferred in children |
| 3 | Co-trimoxazole | Widely resistant Shigella strains; no longer first-line in most areas |
| 4 | Ampicillin | High resistance rates; not reliable |
| 5 | Ceftriaxone | IV route; reserved for severe/resistant cases |
P DRUG SELECTION
| # | Drugs in Fluoroquinolone Group | Reason to Select / Reject |
|---|---|---|
| 1 | Ciprofloxacin ✅ SELECTED | Most used fluoroquinolone for GI infections; oral; well-studied in shigellosis |
| 2 | Norfloxacin | Good for GI infections; lower systemic bioavailability |
| 3 | Ofloxacin | Equally effective; alternative |
| 4 | Levofloxacin | Broader spectrum; reserved for respiratory infections usually |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Fluoroquinolones |
| P Drug | Ciprofloxacin |
| Drug (Mechanism) | Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV → prevents DNA replication, transcription, and repair → bactericidal |
| Efficacy | Shortens illness duration by 2-3 days; reduces fecal shedding; highly effective against Shigella sonnei and flexneri; short course (3-5 days) sufficient |
| Safety | Adverse Reactions: GI disturbance (nausea, diarrhea), headache, dizziness, photosensitivity, QTc prolongation, tendinopathy/tendon rupture (especially Achilles), peripheral neuropathy; Avoid in children <12 yrs (cartilage damage), pregnancy, epilepsy |
| Suitability | Oral; ORS must accompany treatment; avoid antidiarrheals (loperamide) in bloody dysentery |
| Cost | Very cheap as generic; widely available |
| Dose & Frequency | 500 mg BD (twice daily) for 3-5 days |
9. TYPHOID FEVER
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Fluoroquinolones ✅ SELECTED | Bactericidal; excellent intracellular penetration (where Salmonella resides in macrophages); short course |
| 2 | Azithromycin | WHO recommended for uncomplicated typhoid; preferred in children and MDR cases |
| 3 | Third-generation cephalosporins (Ceftriaxone) | IV; for severe/complicated typhoid or quinolone-resistant strains |
| 4 | Chloramphenicol | Historically first-line; high resistance; bone marrow toxicity; obsolete |
| 5 | Co-trimoxazole | Significant resistance; backup only |
P DRUG SELECTION
| # | Drugs in Fluoroquinolone Group | Reason to Select / Reject |
|---|---|---|
| 1 | Ciprofloxacin ✅ SELECTED | First-line for susceptible Salmonella typhi; oral; well-studied |
| 2 | Ofloxacin | Equally effective alternative |
| 3 | Levofloxacin | Option for quinolone-resistant strains at higher doses |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Fluoroquinolones |
| P Drug | Ciprofloxacin |
| Drug (Mechanism) | Inhibits DNA gyrase and topoisomerase IV; bactericidal; achieves high intracellular concentrations in macrophages where Salmonella typhi resides and multiplies |
| Efficacy | Defervescence in 3-5 days; bacteriological clearance; low relapse rate; shorter course than chloramphenicol |
| Safety | Adverse Reactions: Same as in shigellosis - GI upset, headache, photosensitivity, QTc prolongation, tendon rupture, peripheral neuropathy. Avoid in children, pregnancy |
| Suitability | Oral route; 7-10 days for typhoid (longer than dysentery); not suitable in quinolone-resistant typhoid (increasing in India) |
| Cost | Very cheap |
| Dose & Frequency | 500 mg BD for 7-10 days |
10. PULMONARY EDEMA DUE TO LEFT-SIDED CHF
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Loop Diuretics ✅ SELECTED | Most potent diuretics; IV route; dual mechanism (early venodilation + diuresis); drug of choice for acute pulmonary edema |
| 2 | Morphine | Previously used; reduces anxiety, venodilates; now controversial due to respiratory depression risk |
| 3 | IV Nitrates (Nitroglycerine) | Useful venodilator; adjunct to furosemide in acute setting |
| 4 | Thiazide diuretics | Less potent; oral only; not suitable for acute emergency |
| 5 | ACE inhibitors | Long-term CHF management; not acute emergency drugs |
P DRUG SELECTION
| # | Drugs in Loop Diuretic Group | Reason to Select / Reject |
|---|---|---|
| 1 | Furosemide (Frusemide) ✅ SELECTED | Most widely used loop diuretic; IV form available; best studied in pulmonary edema |
| 2 | Torsemide | Better oral bioavailability; longer acting; but less IV data |
| 3 | Bumetanide | Equally potent; 1 mg = 40 mg furosemide; alternative |
| 4 | Ethacrynic acid | Only loop diuretic without sulfa group; reserved for sulfa allergy |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Loop Diuretics |
| P Drug | Furosemide (Frusemide) |
| Drug (Mechanism) | Inhibits Na+/K+/2Cl- cotransporter (NKCC2) in thick ascending limb of Loop of Henle → massive natriuresis and diuresis. Early effect (within 5 min IV): venodilation via prostaglandin release → reduces preload before diuresis starts |
| Efficacy | Most powerful diuretic; dramatically reduces pulmonary venous congestion; relieves dyspnea rapidly; IV onset within 5 min; diuresis in 30 min |
| Safety | Adverse Reactions: Hypokalemia (most important), hyponatremia, hypomagnesemia, hypocalcemia, hyperuricemia (precipitates gout), hyperglycemia, metabolic alkalosis, ototoxicity (high IV doses - dose-related, usually reversible), dehydration, postural hypotension; Contraindicated in anuria |
| Suitability | IV route in acute setting; monitor urine output, electrolytes, creatinine; replace potassium; suitable for all adults with normal or high urine output |
| Cost | Extremely cheap; universally available |
| Dose & Frequency | Acute: 40 mg IV slow (over 2 min); repeat with 80 mg IV if no response in 30 min. Maintenance: 20-80 mg OD orally |
11. HYPERTENSION IN PREGNANT WOMAN (PREECLAMPSIA)
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Centrally Acting Alpha-2 Agonists ✅ SELECTED | Methyldopa - proven safety in all trimesters; most studied drug in obstetric hypertension |
| 2 | Calcium Channel Blockers (Nifedipine) | Alternative for chronic HTN in pregnancy; also used for acute severe HTN |
| 3 | Beta-blockers (Labetalol) | Used for acute management; oral labetalol is second-line for chronic HTN in pregnancy |
| 4 | ACE inhibitors / ARBs | ABSOLUTELY CONTRAINDICATED in pregnancy (teratogenic - renal agenesis, oligohydramnios) |
| 5 | Thiazide diuretics | Avoid in pregnancy; reduce plasma volume, worsen uteroplacental perfusion |
P DRUG SELECTION
| # | Drugs in Alpha-2 Agonist Group / Safe in Pregnancy | Reason to Select / Reject |
|---|---|---|
| 1 | Methyldopa ✅ SELECTED | Most studied; proven fetal safety over decades; WHO recommended for chronic HTN in pregnancy |
| 2 | Clonidine | Also alpha-2 agonist; less data in pregnancy; risk of rebound hypertension |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Centrally Acting Alpha-2 Agonists |
| P Drug | Methyldopa |
| Drug (Mechanism) | Prodrug → converted to α-methyl-norepinephrine in CNS → activates central α2 receptors → reduces sympathetic outflow → decreases peripheral vascular resistance and cardiac output → lowers BP |
| Efficacy | Effective antihypertensive; maintains uteroplacental blood flow; no adverse fetal effects shown in long-term follow-up studies; first-line for CHRONIC HTN in pregnancy |
| Safety | Adverse Reactions: Sedation (most common), dry mouth, postural hypotension, bradycardia, hemolytic anemia (Coombs positive - 20% patients), hepatitis/hepatotoxicity (rare but serious), depression, rebound hypertension on sudden withdrawal; SAFE for fetus (Category B) |
| Suitability | Drug of CHOICE for chronic HTN in pregnancy; for acute severe HTN (BP >160/110 mmHg) in preeclampsia - use IV Labetalol or IV Hydralazine |
| Cost | Cheap, widely available |
| Dose & Frequency | 250 mg BD-TDS initially; maintenance 500 mg - 2g/day in 2-4 divided doses |
12. STABLE ANGINA
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Beta-Adrenergic Blockers ✅ SELECTED | Reduce myocardial O2 demand; also reduce mortality post-MI; no tolerance; most evidence |
| 2 | Nitrates (Long-acting - Isosorbide dinitrate) | Effective antianginal; but tolerance develops with regular use; no mortality benefit |
| 3 | Calcium Channel Blockers (Amlodipine) | Good for vasospastic + stable angina; first-line when beta-blockers contraindicated |
| 4 | Ranolazine | Second-line; inhibits late Na+ current; for refractory angina |
| 5 | Ivabradine | Pure heart rate reduction; second-line or add-on |
P DRUG SELECTION
| # | Drugs in Beta-Blocker Group | Reason to Select / Reject |
|---|---|---|
| 1 | Atenolol ✅ SELECTED | Cardioselective β1 blocker; OD dosing; no CNS side effects; well tolerated |
| 2 | Metoprolol | Also cardioselective; BD dosing; equally effective |
| 3 | Propranolol | Non-selective; causes bronchospasm; more side effects; avoid in asthma |
| 4 | Bisoprolol | Most cardioselective; preferred in patients with mild COPD |
| 5 | Carvedilol | Alpha + beta blocker; preferred in heart failure with angina |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Beta-Adrenergic Blockers (Beta-1 selective) |
| P Drug | Atenolol |
| Drug (Mechanism) | Selective β1 adrenergic receptor blocker → reduces heart rate, myocardial contractility, and cardiac output → decreases myocardial O2 demand; increases diastolic filling time → improves subendocardial perfusion |
| Efficacy | Prevents exercise-induced angina; reduces angina frequency; reduces mortality post-MI; no tolerance unlike nitrates |
| Safety | Adverse Reactions: Bradycardia, heart block, cold extremities, fatigue, depression, erectile dysfunction, masks hypoglycemic symptoms in diabetics, rebound angina/MI on abrupt withdrawal. Contraindicated: Asthma/COPD, bradycardia <50/min, AV block (2nd/3rd degree), decompensated heart failure, Prinzmetal (vasospastic) angina |
| Suitability | First-line for stable angina; especially preferred with co-existing hypertension, post-MI, tachycardia; once daily dosing; taper gradually on stopping |
| Cost | Very cheap; widely available |
| Dose & Frequency | 25-100 mg OD (once daily) |
13. PARKINSONISM
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Dopamine Precursor + Decarboxylase Inhibitor ✅ SELECTED | Levodopa + Carbidopa = most effective symptomatic treatment; gold standard |
| 2 | Dopamine Agonists (Pramipexole, Ropinirole) | Preferred in young patients (<60 yrs) to delay levodopa; less effective than levodopa |
| 3 | MAO-B Inhibitors (Selegiline, Rasagiline) | Mild symptomatic benefit; neuroprotective?; adjunct use |
| 4 | COMT Inhibitors (Entacapone) | Used to extend levodopa effect; not monotherapy |
| 5 | Anticholinergics (Benzhexol/Trihexyphenidyl) | Only for tremor-dominant young patients; not effective for bradykinesia/rigidity |
| 6 | Amantadine | Mild benefit; antidyskinesia effect useful; not potent enough as monotherapy |
P DRUG SELECTION
| # | Drugs in Dopamine Precursor Group | Reason to Select / Reject |
|---|---|---|
| 1 | Levodopa + Carbidopa ✅ SELECTED | Most effective combination; standard of care; reduces peripheral conversion of levodopa → more drug to brain, fewer peripheral side effects |
| 2 | Levodopa alone (without DCI) | Much higher doses needed; more peripheral side effects; obsolete |
| 3 | Levodopa + Benserazide (Madopar) | Equally effective alternative combination |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Dopamine Precursor + Peripheral Decarboxylase Inhibitor (DCI) |
| P Drug | Levodopa + Carbidopa (Syndopa, Sinemet) |
| Drug (Mechanism) | Levodopa crosses BBB → converted to dopamine by DOPA decarboxylase in striatum → replenishes depleted dopamine → restores dopamine-acetylcholine balance. Carbidopa: peripheral DOPA decarboxylase inhibitor → prevents peripheral levodopa conversion → reduces peripheral side effects and increases CNS bioavailability by 75% |
| Efficacy | Most effective drug for all cardinal features (tremor, rigidity, bradykinesia, postural instability); dramatically improves quality of life; gold standard for PD motor symptoms |
| Safety | Adverse Reactions: Nausea, vomiting (early), postural hypotension, cardiac arrhythmias. Long-term (>5 yrs): Wearing-off phenomenon, on-off fluctuations, dyskinesias (peak-dose), hallucinations, psychosis, impulse control disorders; Avoid in narrow-angle glaucoma, psychosis |
| Suitability | Best for elderly (>60 yrs) with significant functional impairment; in younger patients, delay levodopa - use dopamine agonists first; dose titration required |
| Cost | Moderately priced; generic widely available |
| Dose & Frequency | Carbidopa 25 mg + Levodopa 100 mg (1 tablet) TDS initially with meals; titrate up every 2-4 weeks; usual maintenance up to 4-8 tablets/day |
14. OSTEOPOROSIS
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Bisphosphonates ✅ SELECTED | Antiresorptive; best evidence for fracture reduction; first-line per all guidelines |
| 2 | SERMs (Raloxifene) | Only vertebral fracture prevention; no hip fracture benefit; DVT risk |
| 3 | Teriparatide (PTH analog) | Anabolic; most effective but expensive; injectable; only 2-yr course |
| 4 | Denosumab (anti-RANK-L) | Highly effective; injectable every 6 months; expensive; rebound if stopped |
| 5 | Hormone Replacement Therapy (Estrogen) | Effective but breast cancer, DVT risks; not first-line |
| 6 | Calcium + Vitamin D alone | Supplementation only; not sufficient as monotherapy for osteoporosis |
P DRUG SELECTION
| # | Drugs in Bisphosphonate Group | Reason to Select / Reject |
|---|---|---|
| 1 | Alendronate ✅ SELECTED | Most evidence base; oral weekly dosing; reduces vertebral AND hip fractures; generic available |
| 2 | Risedronate | Similar efficacy; weekly or monthly; alternative |
| 3 | Ibandronate | Monthly oral or quarterly IV; no proven hip fracture benefit |
| 4 | Zoledronate | Annual IV infusion; most potent; for patients unable to take oral bisphosphonates |
| 5 | Etidronate | Oldest bisphosphonate; first generation; less potent; rarely used now |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Bisphosphonates (Anti-resorptive agents) |
| P Drug | Alendronate (Alendronic acid) |
| Drug (Mechanism) | Nitrogen-containing bisphosphonate → absorbed into bone matrix → taken up by osteoclasts → inhibits farnesyl pyrophosphate synthase (mevalonate pathway) → osteoclast apoptosis → reduced bone resorption → increased bone mineral density |
| Efficacy | Reduces vertebral fracture risk by 50%, hip fracture risk by 47%; increases BMD at spine and hip; most studied bisphosphonate |
| Safety | Adverse Reactions: Esophageal irritation/ulceration (most important oral ADR), GERD, abdominal pain; Osteonecrosis of the jaw (ONJ - rare, with prolonged use); Atypical femoral fractures (with >5 yrs use); Atrial fibrillation (rare); Hypocalcemia. Strict administration rules required |
| Suitability | First-line for postmenopausal osteoporosis and glucocorticoid-induced osteoporosis; weekly dosing improves compliance; MUST give with calcium 1000-1200 mg/day + Vit D 800 IU/day |
| Cost | Cheap; weekly generic widely available |
| Dose & Frequency | 70 mg orally ONCE WEEKLY - Take first thing in morning, fasting, with full glass plain water, sit/stand upright for 30 min, eat nothing for 30 min |
15. OSTEOARTHRITIS OF BOTH KNEES
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Simple Analgesics (Non-opioid) ✅ SELECTED | Paracetamol - safest first-line analgesic per ACR/EULAR guidelines; no GI/CV/renal risks |
| 2 | NSAIDs (Ibuprofen, Diclofenac) | More effective for inflammation; but GI, cardiovascular, renal risks especially in elderly |
| 3 | Topical NSAIDs (Diclofenac gel) | Good for localized joint pain; fewer systemic effects; alternative first-line |
| 4 | Opioids | For severe refractory pain only; dependence risk; not first-line |
| 5 | Intra-articular corticosteroids | For acute flare-ups; not regular treatment |
| 6 | Duloxetine (SNRI) | For central sensitization pain in OA; adjunct |
P DRUG SELECTION
| # | Drugs in Simple Analgesic Group | Reason to Select / Reject |
|---|---|---|
| 1 | Paracetamol (Acetaminophen) ✅ SELECTED | Safest; suitable for elderly; no GI ulceration; well tolerated; first-line |
| 2 | Tramadol (weak opioid) | Moderate-severe OA pain; dependence risk; only if paracetamol insufficient |
| 3 | Codeine | Opioid; not first-line; constipation, dependence |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Simple Analgesics (Non-opioid, Non-NSAID) |
| P Drug | Paracetamol (Acetaminophen) |
| Drug (Mechanism) | Inhibits COX enzymes in CNS (central mechanism); activates descending serotonergic pain pathways; possibly acts on cannabinoid system (AM404 metabolite); Analgesic and antipyretic - NO peripheral anti-inflammatory action |
| Efficacy | Effective for mild-moderate OA pain; reduces pain and improves function; first-line per ACR 2019 and EULAR OA guidelines; effect size modest but safety profile unmatched |
| Safety | Adverse Reactions: SAFEST analgesic - no GI ulceration, no platelet inhibition, no renal prostaglandin inhibition. Main risk: Hepatotoxicity in overdose (>7.5-10 g acute) via NAPQI metabolite - can cause fulminant hepatic failure; risk increased with alcohol, fasting, hepatic disease; fixed drug eruption (rare rash) |
| Suitability | Drug of CHOICE for OA in elderly, peptic ulcer patients, renal impairment, cardiac disease, anticoagulant therapy; safe in all age groups; scheduled dosing (not PRN) more effective |
| Cost | Extremely cheap; universally available |
| Dose & Frequency | 500 mg - 1g TDS to QID (three to four times daily); maximum 4g/day; with food if GI upset |
16. ACUTE GOUTY ARTHRITIS
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | NSAIDs ✅ SELECTED | Most effective for acute gout; rapid anti-inflammatory; first-line for uncomplicated acute attack |
| 2 | Colchicine | Highly effective; specifically inhibits microtubule assembly and neutrophil migration; preferred alternative when NSAIDs contraindicated |
| 3 | Corticosteroids (Oral Prednisolone / Intra-articular) | When both NSAIDs and colchicine are contraindicated; equally effective |
| 4 | IL-1 inhibitors (Anakinra, Canakinumab) | Biologics for refractory gout; expensive; not routine |
| 5 | Urate-lowering drugs (Allopurinol) | NOT for acute attack - may prolong/worsen acute attack; for chronic prophylaxis only |
P DRUG SELECTION
| # | Drugs in NSAID Group (for Gout) | Reason to Select / Reject |
|---|---|---|
| 1 | Indomethacin ✅ SELECTED | Most potent NSAID; additional mechanism of inhibiting urate crystal phagocytosis; historical drug of choice for gout |
| 2 | Naproxen | Also effective; better GI profile than indomethacin; modern alternative |
| 3 | Etoricoxib | COX-2 selective; less GI risk; effective in acute gout; good option in elderly |
| 4 | Diclofenac | Effective; available widely |
| 5 | Ibuprofen | Less potent for acute gout; not ideal |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | NSAIDs (Non-selective COX inhibitors) |
| P Drug | Indomethacin |
| Drug (Mechanism) | Potent non-selective COX-1 and COX-2 inhibitor → reduces prostaglandin synthesis; ALSO inhibits urate crystal phagocytosis by neutrophils and blocks neutrophil migration into the joint → dual anti-inflammatory mechanism in gout |
| Efficacy | Most effective NSAID for acute gout; pain relief begins within hours; swelling and redness reduce within 24-48 hrs |
| Safety | Adverse Reactions: GI irritation, peptic ulceration, GI bleeding (highest GI risk among NSAIDs), headache, dizziness, confusion (especially elderly), fluid retention, edema, hypertension, hyperkalemia, acute kidney injury, platelet inhibition; Avoid in peptic ulcer, renal failure, elderly, anticoagulant users |
| Suitability | Short course (5-7 days) only; take with food; combine with PPI (omeprazole 20 mg OD) for GI protection; Do NOT start allopurinol during acute attack |
| Cost | Very cheap; widely available |
| Dose & Frequency | 50 mg TDS (three times daily) for 2-3 days, then taper to 25 mg TDS for 3-4 more days; or 75 mg SR BD for 5-7 days |
17. RHEUMATOID ARTHRITIS
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | DMARDs (Conventional Synthetic) ✅ SELECTED | Methotrexate - anchor DMARD; slows erosion; modifies disease; best evidence; cost-effective |
| 2 | Biological DMARDs (Anti-TNF - Adalimumab, Etanercept) | More effective; for MTX-refractory cases; very expensive; infection risk |
| 3 | JAK Inhibitors (Tofacitinib, Baricitinib) | Oral biologics; for failure of conventional DMARDs; expensive |
| 4 | NSAIDs | For symptom relief only; do NOT modify disease or prevent erosions |
| 5 | Corticosteroids | Bridge therapy; for disease flares; not long-term monotherapy |
| 6 | Hydroxychloroquine, Sulfasalazine | Milder DMARDs; often combined with MTX in triple therapy |
P DRUG SELECTION
| # | Drugs in Conventional DMARD Group | Reason to Select / Reject |
|---|---|---|
| 1 | Methotrexate (MTX) ✅ SELECTED | Anchor drug; most widely used; weekly dosing; best long-term evidence; cheap |
| 2 | Hydroxychloroquine (HCQ) | Mild DMARD; for early/mild RA; combined with MTX in triple therapy |
| 3 | Sulfasalazine | Moderate DMARD; alternative; combined with MTX |
| 4 | Leflunomide | Similar efficacy to MTX; daily oral; liver toxicity; alternative when MTX intolerant |
| 5 | Azathioprine | Immunosuppressive; less commonly used; more side effects |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Conventional Synthetic DMARDs (Disease Modifying Anti-Rheumatic Drugs) |
| P Drug | Methotrexate (MTX) |
| Drug (Mechanism) | Folate antagonist → inhibits dihydrofolate reductase (DHFR) → reduces purine synthesis → inhibits lymphocyte proliferation and pro-inflammatory cytokine production (IL-1, IL-6, TNF-α); also increases extracellular adenosine (anti-inflammatory) |
| Efficacy | Gold standard / anchor DMARD for RA; reduces swollen joint count, tender joint count, ESR/CRP; slows radiological erosion progression; improves functional score; most widely used DMARD worldwide |
| Safety | Adverse Reactions: Nausea, vomiting, mucositis/oral ulcers (most common); Hepatotoxicity - elevated LFTs, cirrhosis (with long-term cumulative dose); Bone marrow suppression - pancytopenia; MTX pneumonitis (interstitial lung disease - most serious acute complication); Teratogenicity (Category X - causes abortions, fetal malformations); Alopecia; Renal toxicity. Folic acid 5 mg/day (on non-MTX days) MUST be given to reduce mucositis/hepatotoxicity |
| Suitability | Weekly dosing (not daily); must avoid alcohol (hepatotoxicity); requires regular monitoring - LFT, CBC, creatinine every 4-8 weeks; effective contraception mandatory (both sexes); stop 3 months before planned pregnancy |
| Cost | Very cheap; generic widely available |
| Dose & Frequency | 7.5-25 mg ONCE WEEKLY orally; start at 7.5-10 mg/week; increase by 2.5 mg every 4-6 weeks based on response and tolerance |
18. TYPE 2 DIABETES MELLITUS (Maturity Onset Diabetes)
P GROUP SELECTION
| # | Possible P Groups | Reason to Select / Reject |
|---|---|---|
| 1 | Biguanides ✅ SELECTED | Metformin - first-line per ADA, IDF, WHO; no hypoglycemia; cardioprotective; cheapest |
| 2 | Sulfonylureas (Glipizide, Gliclazide) | Effective but causes hypoglycemia; weight gain; second-line |
| 3 | DPP-4 inhibitors (Sitagliptin) | Well tolerated; no hypoglycemia; weight neutral; but expensive |
| 4 | SGLT-2 inhibitors (Empagliflozin) | Cardioprotective + renoprotective; added after metformin in CV risk patients |
| 5 | GLP-1 agonists (Liraglutide) | Weight loss + CV benefit; injectable; expensive |
| 6 | Thiazolidinediones (Pioglitazone) | Insulin sensitizer; weight gain, fluid retention, fracture risk |
| 7 | Insulin | Required when oral agents fail or in ketosis-prone DM |
P DRUG SELECTION
| # | Drugs in Biguanide Group | Reason to Select / Reject |
|---|---|---|
| 1 | Metformin ✅ SELECTED | The ONLY biguanide in clinical use; phenformin and buformin withdrawn due to severe lactic acidosis; metformin has excellent safety record |
| 2 | Phenformin | Withdrawn from market; high lactic acidosis risk |
| 3 | Buformin | Withdrawn from market |
FINAL P DRUG TABLE
| Category | Details |
|---|---|
| P Group | Biguanides |
| P Drug | Metformin |
| Drug (Mechanism) | Activates AMP-activated protein kinase (AMPK) via inhibition of mitochondrial complex I → primarily reduces hepatic gluconeogenesis (main mechanism); secondarily improves peripheral insulin sensitivity in muscle and fat; decreases intestinal glucose absorption; does NOT stimulate insulin secretion → NO hypoglycemia |
| Efficacy | Reduces HbA1c by 1-2%; first-line per all guidelines (ADA 2024, IDF, NICE); cardiovascular protective effect (UKPDS trial showed reduced MI, mortality); weight neutral or causes mild weight loss; reduces diabetes progression in prediabetes |
| Safety | Adverse Reactions: GI side effects - nausea, vomiting, diarrhea, metallic taste, abdominal cramps (most common, dose-dependent, take with food, use XR formulation); Lactic acidosis (most serious but rare - incidence 0.03/1000 patient-years; occurs in overdose or when contraindications are ignored); Vitamin B12 deficiency with long-term use; No hypoglycemia (major safety advantage). Contraindications: eGFR <30 (accumulation → lactic acidosis), severe hepatic disease, alcoholism, acute illness, IV contrast (withhold 48 hrs before and after) |
| Suitability | Drug of CHOICE for T2DM - especially overweight/obese; suitable for most patients; take with meals to minimize GI effects; use extended release (XR) for better GI tolerability |
| Cost | Extremely cheap; most widely used oral antidiabetic worldwide |
| Dose & Frequency | 500 mg OD-BD with meals initially; titrate every 2 weeks; target 1000 mg BD (maintenance); maximum 2500 mg/day. XR: 500-2000 mg OD with evening meal |
MASTER QUICK REFERENCE TABLE
| # | Condition | P Group Selected | P Drug Selected | Dose & Frequency |
|---|---|---|---|---|
| 1 | Vertigo | Antihistaminics | Cinnarizine | 25 mg TDS |
| 2 | Mild Migraine | NSAIDs | Aspirin | 600-900 mg stat, repeat 4-6 hrly |
| 3 | Severe Migraine | Triptans (5-HT1B/D agonists) | Sumatriptan | 50-100 mg oral stat; max 300 mg/day |
| 4 | Acute Congestive Glaucoma | CA Inhibitor + Miotic | Acetazolamide + Pilocarpine 2% | 500 mg IV + 1 drop q15 min × 4 |
| 5 | Open Angle Glaucoma | Prostaglandin Analogs | Latanoprost 0.005% | 1 drop OD at bedtime |
| 6 | Anaphylactic Shock | Catecholamines | Adrenaline 1:1000 | 0.5 mg IM, repeat q5-15 min |
| 7 | Uncomplicated Falciparum Malaria | ACT | Artemether + Lumefantrine | 4 tabs at 0,8,24,36,48,60 hrs |
| 8 | Shigellosis | Fluoroquinolones | Ciprofloxacin | 500 mg BD × 3-5 days |
| 9 | Typhoid Fever | Fluoroquinolones | Ciprofloxacin | 500 mg BD × 7-10 days |
| 10 | Pulmonary Edema / CHF | Loop Diuretics | Furosemide | 40-80 mg IV stat |
| 11 | HTN in Pregnancy | Alpha-2 Agonists | Methyldopa | 250 mg BD-TDS |
| 12 | Stable Angina | Beta-1 Blockers | Atenolol | 25-100 mg OD |
| 13 | Parkinsonism | Dopamine Precursor + DCI | Levodopa + Carbidopa | 100/25 mg TDS (titrate up) |
| 14 | Osteoporosis | Bisphosphonates | Alendronate | 70 mg once weekly |
| 15 | Osteoarthritis | Simple Analgesics | Paracetamol | 500 mg-1g TDS-QID; max 4g/day |
| 16 | Acute Gout | NSAIDs | Indomethacin | 50 mg TDS × 5-7 days |
| 17 | Rheumatoid Arthritis | DMARDs | Methotrexate | 7.5-25 mg once weekly |
| 18 | Type 2 DM | Biguanides | Metformin | 500 mg OD initially; 1000 mg BD maintenance |
Exam Tip: Always explain WHY you selected the P group over others, and WHY you selected the P drug over other drugs in that group. The tables above give you exactly that justification. Best of luck tomorrow! 🎯
This is a shared conversation. Sign in to Orris to start your own chat.